Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

3Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML ( p<.0011) and better overall survival (OS, p=011). OS difference persisted after matching on age, sex, IPSS and % marrow blast ( p=031). Thus, in MDS other than RARS-T, JAK2V617F mutation may be associated with favorable outcome. © 2013 The Authors.

Cite

CITATION STYLE

APA

de Renzis, B., Mansat-De Mas, V., Wattel, E., Beyne-Rauzy, O., Knoops, L., Cabrespine, A., … Fenaux, P. (2013). Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study. Leukemia Research Reports, 2(2), 64–66. https://doi.org/10.1016/j.lrr.2013.06.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free